Among the latest health care trends seeking to advance “individualized medicine” are private companies marketing genetic testing directly to patients. The mail-in kits, with price tags as high as $2,500, use a saliva specimen to identify small variations in the human genome associated with heightened risk for diseases such as diabetes and prostate cancer.